BMN 673

DRUG5 trials

Conditions

Acute Myeloid LeukemiaAdvanced Breast CancerAdvanced Ovarian CancerAdvanced Solid TumorsChronic Lymphocytic LeukemiaEndometrial CancerFallopian Tube Serous AdenocarcinomaHigh Grade Ovarian Serous Adenocarcinoma

Early Phase 1

Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

CompletedNCT02316834

M.D. Anderson Cancer CenterFallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Ovarian Mass +16

Start: 2015-06-02End: 2022-01-14Updated: 2022-02-24

Phase 1

Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies

CompletedNCT01399840

PfizerAcute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma +1

Start: 2011-06-30End: 2014-05-31Updated: 2017-09-15

Study of BMN 673, a PARP Inhibitor, in Healthy Adult Male Volunteers

CompletedNCT01776437

PfizerHuman Volunteers

Start: 2013-02-28End: 2013-07-31Updated: 2017-07-28

Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations

CompletedNCT01989546

National Cancer Institute (NCI)Advanced Breast Cancer, Advanced Ovarian Cancer, Advanced Solid Tumors +1

Start: 2014-02-04End: 2020-03-26Updated: 2021-02-23

Phase 2

A Parp Inhibitor (BMN 673) for Inoperable Advanced eNDometrial cAncer

WithdrawnNCT02127151

University College, LondonEndometrial Cancer

Start: 2014-10-01End: 2017-05-01Updated: 2021-08-06

2023-11-275 citations

A Phase I Trial of Talazoparib in Patients with Advanced Hematologic Malignancies

International Journal of Hematologic Oncology2021-09-017 citations

Systems approach to rational combination therapy: PARP inhibitors.

2020-06-0133 citations

Population pharmacokinetic analyses for talazoparib (TALA) in cancer patients

Annals of Oncology2018-10-016 citations

BMN 673

Sponsors

Conditions

Early Phase 1

Phase 1

Phase 2

Related Papers